Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma
The Journal of Dermatology,  Clinical Article

Wada H et al. – Vorinostat was well tolerated at a dose of 400 mg p.o. once daily and showed potential efficacy in Japanese patients with cutaneous T–cell lymphoma (CTCL), warranting further investigation.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Dermatology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Dermatology Articles

Indexed Journals in Dermatology: American Journal of Clinical Dermatology, Contact Dermatitis, Dermatologic Surgerymore